Display options
Cite
Feng YM, Chen TH, Berman D, et al. Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report. Front Oncol. 2021;11:620212doi: 10.3389/fonc.2021.620212.
Feng, Y. M., Chen, T. H., Berman, D., Chou, C. K., Liao, K. S., Hsieh, M. C., & Chen, C. Y. (2021). Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report. Frontiers in oncology, 11620212. https://doi.org/10.3389/fonc.2021.620212
Feng, Yu-Min, et al. "Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report." Frontiers in oncology vol. 11 (2021): 620212. doi: https://doi.org/10.3389/fonc.2021.620212
Feng YM, Chen TH, Berman D, Chou CK, Liao KS, Hsieh MC, Chen CY. Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report. Front Oncol. 2021 Oct 20;11:620212. doi: 10.3389/fonc.2021.620212. eCollection 2021. PMID: 34745929; PMCID: PMC8563693.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2021 Oct 20;11:620212. doi: 10.3389/fonc.2021.620212. eCollection 2021.

Efficacy of Cyproheptadine Monotherapy in Hepatocellular Carcinoma With Bone Metastasis: A Case Report.

Frontiers in oncology

Yu-Min Feng, Tsung-Hsien Chen, Dara Berman, Chu-Kuang Chou, Kai-Sheng Liao, Ming-Chih Hsieh, Chi-Yi Chen

Affiliations

  1. Divisions of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  2. Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  3. Charles H. Dyson School of Applied Economics and Management, SC Johnson College of Business, Cornell University, Ithaca, NY, United States.
  4. Clinical Trial Center, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  5. Department of Nursing, Chung-Jen Junior College of Nursing, Health Sciences and Management, Chiayi, Taiwan.
  6. Department of Pathology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  7. Department of Radiology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.

PMID: 34745929 PMCID: PMC8563693 DOI: 10.3389/fonc.2021.620212

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. Particularly, cases of bone metastasis have poorer prognoses.

CASE PRESENTATION: A 62-year-old woman with suspected advanced HCC accompanied by bone metastasis with severe back pain and sciatica showed disease remission after cyproheptadine monotherapy. Initially, her serum alpha fetal protein (AFP) level was high, reaching up to 17697.62 ng/ml. A dose of 4 mg cyproheptadine, 3 times a day for 17 months was prescribed as the only treatment. Within 3 months, the serum AFP level gradually normalized down to 4.3 ng/ml. Both liver biopsy and bone biopsies were subsequently performed after 2 weeks of cyproheptadine. The results showed no malignancy. During the 34 months of follow-ups, the serum AFP remained normal in the range of 1.05 to 2.86 ng/ml. The patient has survived for 5 years without back pain and sciatica thus far.

CONCLUSIONS: This is the first report to investigate a successful clinical approach in cyproheptadine monotherapy for an advanced HCC patient with bone metastasis. We recommend cyproheptadine as a potential anti-HCC agent for the treatment of HCC with bone metastasis, but more related studies such as prospectively clinical trials, and ideally randomized trials are still needed.

Copyright © 2021 Feng, Chen, Berman, Chou, Liao, Hsieh and Chen.

Keywords: alpha fetal protein; case report; cyproheptadine; hepatocellular carcinoma; monotherapy

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declare

References

  1. Nat Med. 2008 Jul;14(7):756-61 - PubMed
  2. BMC Cancer. 2015 Mar 17;15:134 - PubMed
  3. Am J Cancer Res. 2017 Mar 01;7(3):584-602 - PubMed
  4. N Engl J Med. 2019 Apr 11;380(15):1450-1462 - PubMed
  5. BMJ Case Rep. 2012 Oct 12;2012: - PubMed
  6. Mediators Inflamm. 2018 Aug 27;2018:9524075 - PubMed
  7. Cancer Lett. 2016 Jan 1;370(1):56-65 - PubMed
  8. J Gastrointest Cancer. 2017 Dec;48(4):321-325 - PubMed
  9. Oncologist. 2020 Mar;25(3):e512-e519 - PubMed
  10. Am J Cancer Res. 2020 Jul 01;10(7):2114-2119 - PubMed
  11. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58 - PubMed
  12. Hepatology. 2008 Dec;48(6):2047-63 - PubMed
  13. Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):53-58 - PubMed
  14. J Hepatol. 2012 Oct;57(4):821-9 - PubMed
  15. Cancers (Basel). 2020 Jun 18;12(6): - PubMed
  16. Nature. 2001 May 17;411(6835):342-8 - PubMed

Publication Types